- Home
- VEON vs RYTM Comparison
VEON vs RYTM Comparison
Compare VEON & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEON
- RYTM
- Stock Information
- Founded
- VEON 1992
- RYTM 2008
- Country
- VEON Netherlands
- RYTM United States
- Employees
- VEON N/A
- RYTM N/A
- Industry
- VEON Telecommunications Equipment
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- VEON Telecommunications
- RYTM Health Care
- Exchange
- VEON Nasdaq
- RYTM Nasdaq
- Market Cap
- VEON 3.3B
- RYTM 3.1B
- IPO Year
- VEON 1996
- RYTM 2017
- Fundamental
- Price
- VEON $46.00
- RYTM $54.54
- Analyst Decision
- VEON Strong Buy
- RYTM Strong Buy
- Analyst Count
- VEON 1
- RYTM 10
- Target Price
- VEON $48.00
- RYTM $66.90
- AVG Volume (30 Days)
- VEON 147.8K
- RYTM 580.8K
- Earning Date
- VEON 11-14-2024
- RYTM 02-20-2025
- Dividend Yield
- VEON N/A
- RYTM N/A
- EPS Growth
- VEON N/A
- RYTM N/A
- EPS
- VEON N/A
- RYTM N/A
- Revenue
- VEON $3,955,000,000.00
- RYTM $112,530,000.00
- Revenue This Year
- VEON $12.10
- RYTM $63.77
- Revenue Next Year
- VEON $7.27
- RYTM $44.91
- P/E Ratio
- VEON $5.46
- RYTM N/A
- Revenue Growth
- VEON 7.36
- RYTM 81.55
- 52 Week Low
- VEON $18.57
- RYTM $35.17
- 52 Week High
- VEON $48.39
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- VEON 75.62
- RYTM 43.02
- Support Level
- VEON $45.08
- RYTM $52.71
- Resistance Level
- VEON $48.39
- RYTM $60.12
- Average True Range (ATR)
- VEON 2.14
- RYTM 2.13
- MACD
- VEON 0.15
- RYTM -0.36
- Stochastic Oscillator
- VEON 77.54
- RYTM 23.48
About VEON VEON Ltd. ADS
VEON Ltd is a provider of mobile and fixed-line connectivity as well as digital services. Currently, the company offers services to customers in the following countries: Pakistan, Ukraine, Kazakhstan, Bangladesh, Uzbekistan, and Kyrgyzstan. The reportable segments currently consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. The company provides services under the Beeline, Kyivstar, Banglalink and Jazz brands.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.